Business Description
Abbott Laboratories
NAICS : 339112
SIC : 3841
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Compare
Compare
Traded in other countries / regions
ABT.Argentina
•
ABT.Austria
•
ABTT34.Brazil
•
ABT.Chile
•
ABL.Germany
•
ABT.Mexico
•
ABT.Switzerland
•
ABT.UK
•
ABT.USA
Description
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.55 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.46 | |||||
| Debt-to-EBITDA | 1.2 | |||||
| Interest Coverage | 19.38 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 5.06 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.7 | |||||
| 3-Year EBITDA Growth Rate | 20.3 | |||||
| 3-Year EPS without NRI Growth Rate | 44.3 | |||||
| 3-Year FCF Growth Rate | 20.4 | |||||
| 3-Year Book Growth Rate | 5.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 1.34 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 0.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.6 | |||||
| 9-Day RSI | 62.34 | |||||
| 14-Day RSI | 57.33 | |||||
| 6-1 Month Momentum % | -13.7 | |||||
| 12-1 Month Momentum % | -11.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | |||||
| Quick Ratio | 1.54 | |||||
| Cash Ratio | 0.75 | |||||
| Days Inventory | 104.85 | |||||
| Days Sales Outstanding | 53.5 | |||||
| Days Payable | 82.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.67 | |||||
| Dividend Payout Ratio | 0.38 | |||||
| 3-Year Dividend Growth Rate | 17.1 | |||||
| Forward Dividend Yield % | 1.69 | |||||
| 5-Year Yield-on-Cost % | 2.88 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.05 | |||||
| Operating Margin % | 22.42 | |||||
| Net Margin % | 18.78 | |||||
| ROE % | 24.31 | |||||
| ROA % | 11.54 | |||||
| ROIC % | 16.52 | |||||
| ROC (Joel Greenblatt) % | 101.92 | |||||
| ROCE % | 17.23 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.27 | |||||
| Forward PE Ratio | 22.52 | |||||
| PE Ratio without NRI | 23.27 | |||||
| Shiller PE Ratio | 45.04 | |||||
| Price-to-Owner-Earnings | 23.96 | |||||
| PEG Ratio | 1.07 | |||||
| PS Ratio | 4.35 | |||||
| PB Ratio | 5.35 | |||||
| Price-to-Tangible-Book | 90.63 | |||||
| Price-to-Free-Cash-Flow | 23.42 | |||||
| Price-to-Operating-Cash-Flow | 19.35 | |||||
| EV-to-EBIT | 19.17 | |||||
| EV-to-Forward-EBIT | 19.53 | |||||
| EV-to-EBITDA | 14.53 | |||||
| EV-to-Forward-EBITDA | 16.86 | |||||
| EV-to-Revenue | 4.45 | |||||
| EV-to-Forward-Revenue | 4.78 | |||||
| EV-to-FCF | 23.94 | |||||
| Price-to-Projected-FCF | 1.77 | |||||
| Price-to-Median-PS-Value | 1.15 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.21 | |||||
| Price-to-Graham-Number | 9.69 | |||||
| Earnings Yield (Greenblatt) % | 5.22 | |||||
| Forward Rate of Return (Yacktman) % | 22.22 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:ABT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 45,548 | ||
| EPS (TTM) ($) | 4.79 | ||
| Beta | 0.71 | ||
| Volatility % | 23.22 | ||
| 14-Day RSI | 57.33 | ||
| 14-Day ATR ($) | 2.03103 | ||
| 20-Day SMA ($) | 109.387 | ||
| 12-1 Month Momentum % | -11.81 | ||
| 52-Week Range ($) | 101.24 - 142.6 | ||
| Shares Outstanding (Mil) | 1,751.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abbott Laboratories Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||